-
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
•
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to RMB 160 million (USD 22 million) through a private placement. The net proceeds from this capital increase are designated for Contract Development and Manufacturing Organization (CDMO) work on innovative peptide drugs, the industrialization of active…
-
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
•
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Shire’s Firazyr (icatibant). This marks a significant milestone as the company becomes the first manufacturer to file for Drug…
